What's fueling the biotech engine-2012 to 2013

Nature Biotechnology

Volumn 32, Issue 1, 2014, Pages 32-39

  Aggarwal, Saurabh Rob ^a,b  

^a Novel Health Strategies LLC   (United States)

^b Institute for Women's Policy Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOSIMILAR AGENT; CYTOKINE; ENZYME; GROWTH FACTOR; HORMONE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE;

ARTICLE; BIOTECHNOLOGY; BLOOD GROUP; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REIMBURSEMENT;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; DRUG INDUSTRY; HUMANS;

EID: 84892170718     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2794     Document Type: Article

References (20)

1. A nonymous. Biosimilar legislation state by state. Nat. Biotechnol. 31, 947 (2013).
2. A ggarwal, S. What's fueling the biotech engine? Nat. Biotechnol. 25, 1097-1104 (2007).
3. A ggarwal, S. What's fueling the biotech engine-2009 to 2010. Nat. Biotechnol. 28, 1165-1171 (2010).
4. A ggarwal, S. What's fueling the biotech engine-2010 to 2011. Nat. Biotechnol. 29, 1083-1089 (2011).
5. A ggarwal, S.R. What's fueling the biotech engine-2011 to 2012. Nat. Biotechnol. 30, 1191-1197 (2012).
6. A ggarwal, S. What's fueling the biotech engine-2008. Nat. Biotechnol. 27, 987-993 (2009).
7. A ggarwal, S. What's fueling the biotech engine-2007. Nat. Biotechnol. 26, 1227-1233 (2008).
8. A nonymous. Building a wall against biosimilars. Nat. Biotechnol. 31, 264 (2013).
9. A nonymous. Bevacizumab is the first agent to signifi cantly improve survival in recurrent cervical cancer. ASCO Daily News (4 June 2013.
10. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541-1550 (2013).
11. Griffiths, C.E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118-128 (2010).
12. F ellner, C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. PT 37, 503-530 (2012).
13. F ox, J.L. Anthrax drug first antibacterial mAb to win approval. Nat. Biotechnol. 31, 8 (2013).
14. Pratley, R.E. et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447-1456 (2010).
15. Volovat, C. et al. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. Clin. Breast Cancer (in the press) (2013).
16. Bach, P.B., Saltz, L.B. & Wittes, R.E. In cancer care, cost matters. The New York Times (12 October 2012).
17. E xperts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-4442 (2013).
18. Powell, J.S. et al. Phase 3 Study of recombinant factor IX Fc fusion protein in hemophilia B. N. Engl. J. Med. doi:10.1056/NEJMoa1305074 (4 December 2013).
19. A nonymous. Failure to launch. Nat. Biotechnol. 31, 1 (2013).
20. Novel Health Strategies United States Health Care Reform Act 2014-2020, (2013).